MetaCure Announces Closing of New Financing Allowing Acceleration of Commercial and Product Development Efforts

ORANGEBURG, N.Y., April 20, 2009 (GLOBE NEWSWIRE) -- MetaCure announced today
that it has recently closed a new round of financing of $20 million from
institutional and private investors that will provide the necessary capital for
realizing its strategic plans. This transaction is part of a US$124.5 million
facility that was provided to a portfolio of affiliated companies. Sarit Molcho
and Amir Shavitzky of the Tel-Aviv law firm of S. Friedman & Co., represented
the companies in the transaction. 

The TANTALUS System, recently launched in major European markets, can provide a
clinical benefit for patients with Type 2 Diabetes and other co-morbidities,
such as obesity. 

"This new funding coupled with the recent European commercial launch and
clinical activities will provide MetaCure with a strong growth opportunity and
will allow the Company to further enhance those activities," stated Dr. Irit
Yaniv, chief operating officer, MetaCure. 

"Establishing TANTALUS as a standard of care for diabesity," said Shai
Policker, vice president of business development, MetaCure, "requires a sales
force that can address the needs of diabetologists, family practitioners and
internists, while providing high quality surgical training in centers of
excellence. These additional resources will facilitate these market development
efforts. MetaCure continues its search for a strategic partner that will enable
wide market access and/or expand product proposition." 

About MetaCure

MetaCure, with offices in U.S., Germany and Israel, is a pioneering medical
device company focused on the development and commercialization of TANTALUS, a
revolutionary implantable device for the treatment of type 2 diabetes and
related metabolic conditions. MetaCure is a leader in the emerging field of
interventional diabetology which explores minimally invasive procedures and
devices for aggressive glucose control and weight loss. Additional information
can be found at www.metacure.com or www.metacure.de. 

Forward-Looking Statements

This press release contains forward-looking statements about MetaCure,
including projections about its business and the diabetes market. Those
forward-looking statements are not guarantees of future performance and actual
results could differ significantly. 

CONTACT:  MetaCure
          Shai Policker, Vice President of Business Development
          (845) 826-0709
          shaip@metacure.com